Grifols Therapeutics Llc

This study tests whether a weekly intravenous dose of a protein (Alpha-1 MP) can slow lung damage in people with emphysema caused by Alpha-1 antitrypsin deficiency. About 345 adults with moderate-to-severe lung disease will receive either a low dose, high dose, or placebo for thr…

This study aimed to measure how a medicine called FANHDI® works in children under 6 with severe von Willebrand disease, a bleeding disorder. The plan was to give the medicine and track its effects over time. However, the study was withdrawn before any participants were enrolled, …

This study looks at the long-term safety of a weekly intravenous treatment for people with a rare genetic condition that causes lung damage (emphysema). About 290 adults who completed a previous study will receive the drug for 2 more years. The main goal is to monitor side effect…